Elucidation of the mucin repertoire produced by the ocular surface epithelia is critical to understand how the eye is protected against environmental insult and infection. A number of reports have established that the stratified squamous epithelia of the human ocular surface synthesize at least three transmembrane mucins, MUC1, MUC4, and MUC16.
7,28 Data obtained in this study provides direct evidence on the expression and regulation of an additional transmembrane mucin, MUC20, at the ocular surface.
We found that MUC20 has a unique distribution compared to other transmembrane mucins at the ocular surface (
Fig. 6). Earlier studies demonstrated that MUC1, MUC4, MUC16 are present along the membranes of the superficial cell layer of the corneal and conjunctival epithelia.
28 Indeed, the localization of MUC16 at the tips of the microplicae in the apical glycocalyx of the corneal epithelium has led to studies and demonstration of the role of this mucin in barrier function.
24,30,31 Based on the protective role ascribed to transmembrane mucins on the tear film interface, we expected that MUC20 would likewise be present along apical membranes on the apical surface of the stratified epithelia. Surprisingly, immunofluorescence microscopy revealed that MUC20 was predominant along the cell membranes of intermediate cell layers of the stratified epithelium, with limited expression on the apical glycocalyx of superficial cells. Further, MUC20 was weakly detected on biotinylated surface proteins from the HCLE and HCjE cell lines and was absent in human tears. These data suggested that, unlike MUC16, a transmembrane glycoprotein with a molecular weight of more than 2.4 MDa, the small MUC20 may not be primarily involved in glycocalyx barrier function at the ocular surface. Recent evidence indicating that transmembrane mucins do not have a redundant role in the protection of the ocular surface, but may have additional functions, supports this hypothesis.
32
Although to our knowledge no specific function has yet been identified for MUC20 at the ocular surface, studies derived from the analysis of its C-terminal domain indicate that MUC20 could be involved in the regulation of the Met signaling pathway. Met is a cell-surface receptor for hepatocyte growth factor (HGF) involved in cell motility.
33 Using a yeast two-hybrid screen, Higuchi et al.
34 showed that the cytoplasmic domain of MUC20 associates with the multifunctional docking site of Met. This interaction prevents the recruitment of the Grb2 adaptor protein to Met; therefore, attenuating the activation of MAPK, inhibiting the expression of matrix metalloproteinases, and preventing the proliferation of kidney epithelial cells induced by HGF. In cornea, HGF is known to facilitate the migration and proliferation of epithelial cells, and to inhibit apoptosis.
35 Consistent with the effect of HGF in human corneas, Met expression has been detected throughout the epithelium.
36 Moreover, expression of Met mRNA in the corneal epithelium is markedly upregulated following epithelial injury
37 but downregulated in human corneas of donors with diabetic retinopathy.
38 Although not within the scope of our current study, it is tempting to speculate that MUC20 expression may have a role in the regulation of Met signaling in ocular surface epithelia through binding to its multifunctional docking site.
Serum contains a number of growth factors, vitamins, and anti-inflammatory factors that have been considered important for corneal and conjunctival integrity.
39 Indeed, eye drops made from autologous serum are used in clinical practice to treat ocular surface disorders, such as persistent epithelial defects or severe dry eyes intractable to conventional therapy.
40 Hori et al.
25 proposed that a mechanism for the efficacy of serum may be due in part to its ability to upregulate expression of the transmembrane mucins MUC1, MUC4, and MUC16 in the human ocular surface epithelia, at the mRNA and protein levels. Interestingly, the pattern of regulation of each mucin was different from the others, suggesting that the three transmembrane mucins are independently regulated.
25 We found that, similar to MUC1 in corneal and conjunctival epithelial cells,
25,26,41 MUC20 mRNA and protein were detectable in cells grown in serum-free conditions. After addition of serum, the expression of MUC20 increased as previously shown with other transmembrane mucins in a process associated with the terminal differentiation of ocular surface epithelia in vitro and in vivo.
25,42 The requirement of serum for the induction of MUC20 expression suggests an important role of serum proteins derived from conjunctival vessels in maintaining proper levels of this mucin at the ocular surface.
In summary, our results indicated that MUC20 is a transmembrane mucin strongly expressed at the ocular surface. It has a unique localization throughout the human corneal and conjunctival epithelia, being predominant in the intermediate cell layers of the stratified epithelia. Moreover, we found that MUC20 expression is differentially regulated during cell stratification and differentiation, and that compared to other transmembrane mucins, it is not released into the tear film. Clearly, further studies are needed to provide direct evidence on the biological roles of MUC20 in ocular surface health and disease.